Objective: To evaluate postoperative hearing outcomes after lateral temporal bone resection (LTBR) with reconstruction of the external auditory canal (EAC) and conductive function for early-stage EAC carcinoma. Methods: We retrospectively examined patients diagnosed with early-stage EAC carcinoma treated with surgery alone between January 2006 and December 2012. Patients who had postoperative adjuvant chemotherapy and/or radiotherapy were excluded. Patients receiving LTBR in combination with tympanoplasty were divided into two groups based on the reconstruction of the EAC with and without (w/o) split-thickness skin grafts (STSGs). Audiological data included the preoperative hearing thresholds and the most recent postoperative hearing thresholds obtained at least 12 months after surgery. The hearing outcome was evaluated based on pure-tone audiograms using the Committee on Hearing and Equilibrium guidelines of the American Academy of Otolaryngology-Head and Neck Surgery for the evaluation of the results of treatment of conductive hearing loss. The postoperative quality of life (QOL) for patients was evaluated using the Glasgow Benefit Inventory (GBI). Results: All patients (n = 15) achieved disease-free survival without significant morbidity or mortality. When we compared the mean air-bone gaps after surgery, those in the STSG group (n = 8) were found to be significantly lower than those in the w/o STSG group (n = 7; p < 0.001). The success rate for postoperative hearing was 75.0% in the STSG group, which was significantly higher than that in the w/o STSG group (p = 0.014). All patients in the w/o STSG group showed stenosis and closure of the EAC at fewer than 10 months after surgery. In contrast, all patients in the STSG group showed preserved conformation of the new EAC for more than 12 months after surgery. When we compared the mean GBI score between the two groups of patients, the overall and general health scores in the STSG group were found to be significantly higher than those in the w/o STSG group (p = 0.021, p = 0.001). Conclusions: Reconstruction of the EAC using a rolled-up STSG technique in combination with tympanoplasty after LTBR is useful for hearing preservation and the observation of locoregional lesions after surgery, resulting in improved QOL for patients. i 2014 S. Karger AG, Basel

Keywords:
External auditory canal carcinoma, Hearing preservation, Early stage, Tympanoplasty, Reconstruction
1.
American Academy of Otolaryngology-Head and Neck Surgery Foundation, Inc: Committee on Hearing and Equilibrium guidelines for the evaluation of results of treatment of conductive hearing loss. Otolaryngol Head Neck Surg 1995;113:186-187.
2.
Barrs DM: Temporal bone carcinoma. Otolaryngol Clin North Am 2001;34:1197-1218.
3.
Bell DR: External auditory canal stenosis and atresia: dual flap surgery. J Otolaryngol 1988;17:19-21.
4.
Gal TJ, Kerschner JE, Futran ND, Bartels LJ, Farrior JB, Ridley MB, Klotch DW, Endicott JN: Reconstruction after temporal bone resection. Laryngoscope 1998;108:476-481.
5.
Hirsch BE, Chang CYJ: Carcinoma of the temporal bone; in Myers EN (ed): Operative Otolaryngol Head Neck Surgery. Philadelphia, Saunders, 1997, pp 1434-1458.
6.
Hoshikawa H, Miyashita T, Mori N: Surgical procedures for external auditory canal carcinoma and the preservation of postoperative hearing. Case Rep Surg 2012;2012:841372.
7.
Iida T, Mihara M, Yoshimatsu H, Narushima M, Koshima I: Reconstruction of the external auditory canal using a super-thin superficial circumflex iliac perforator flap after tumour resection. J Plast Reconstr Aesthet Surg 2013;66:430-433.
8.
Koshima I, Nanba Y, Tsutsui T, Takahashi Y, Urushibara K, Inagawa K, Hamasaki T, Moriguchi T: Superficial circumflex iliac artery perforator flap for reconstruction of limb defects. Plast Reconstr Surg 2004;113:233-240.
9.
Kunst H, Lavieille JP, Marres H: Squamous cell carcinoma of the temporal bone: results and management. Otol Neurotol 2008;29:549-552.
10.
Moody SA, Hirsch BE, Myers EN: Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol 2000;21:582-588.
11.
Nakagawa T, Kumamoto Y, Natori Y, Shiratsuchi H, Toh S, Kakazu Y, Shibata S, Nakashima T, Komune S: Squamous cell carcinoma of the external auditory canal and middle ear: an operation combined with preoperative chemoradiotherapy and a free surgical margin. Otol Neurotol 2006;27:242-248.
12.
Nyrop M, GrHntved A: Cancer of the external auditory canal. Arch Otolaryngol Head Neck Surg 2002;128:834-837.
13.
Pfreundner L, Schwager K, Willner J, Baier K, Bratengeier K, Brunner FX, Flentje M: Carcinoma of the external auditory canal and middle ear. Int J Radiat Oncol Biol Phys 1999;44:777-788.
14.
Robinson K, Gatehouse S, Browning GG: Measuring patient benefit from otorhinolaryngological surgery and therapy. Ann Otol Rhinol Laryngol 1996;105:415-422.
15.
Spector JG: Management of temporal bone carcinomas: a therapeutic analysis of two groups of patients and long-term follow-up. Otolaryngol Head Neck Surg 1991;104:58-66.
16.
Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx 2006;33:251-257.
17.
Zhang B, Tu G, Xu G, Tang P, Hu Y: Squamous cell carcinoma of temporal bone: reported on 33 patients. Head Neck 1999;21:461-466.
18.
Zhang T, Li W, Dai C, Chi F, Wang S, Wang Z: Evidence-based surgical management of T1 or T2 temporal bone malignancies. Laryngoscope 2013;123:244-248.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.